A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B003 Monotherapy, BL-B01D1+SI-B003 Combination Therapy and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
Sponsor: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Listed as NCT06008054, this PHASE2 trial focuses on Colorectal Cancer and Esophageal Cancer and remains actively recruiting participants. Sponsored by Baili-Bio (Chengdu) Pharmaceutical Co., Ltd., it has been updated 9 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Oct 2025 — Present [monthly]
Recruiting PHASE2
-
Jun 2025 — Oct 2025 [monthly]
Recruiting PHASE2
-
Oct 2024 — Jun 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2023 — Jan 2024 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2023 — Dec 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
- Sichuan Baili Pharmaceutical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .